Kyverna Therapeutics Inc is a clinical-stage biopharmaceutical company... Show more
Industry Biotechnology
| 1 Day | |||
|---|---|---|---|
| MFs / NAME | Price $ | Chg $ | Chg % |
| HFDCX | 20.26 | 0.13 | +0.65% |
| Hartford Schroders US MidCap Opps C | |||
| DSHZX | 13.63 | 0.08 | +0.59% |
| Brinker Capital Destinations Shelter Z | |||
| PAADX | 18.03 | 0.01 | +0.06% |
| Franklin Dynamic Asset Allocation Bal R5 | |||
| RRMGX | 86.28 | -0.28 | -0.32% |
| T. Rowe Price Mid-Cap Growth R | |||
| VRREX | 21.21 | -0.12 | -0.56% |
| Virtus Duff & Phelps Real Estate Secs R6 | |||
A.I.dvisor indicates that over the last year, KYTX has been loosely correlated with FDMT. These tickers have moved in lockstep 51% of the time. This A.I.-generated data suggests there is some statistical probability that if KYTX jumps, then FDMT could also see price increases.
| Ticker / NAME | Correlation To KYTX | 1D Price Change % | ||
|---|---|---|---|---|
| KYTX | 100% | -2.54% | ||
| FDMT - KYTX | 51% Loosely correlated | +1.09% | ||
| IMNM - KYTX | 49% Loosely correlated | -1.39% | ||
| PRME - KYTX | 45% Loosely correlated | -3.31% | ||
| EDIT - KYTX | 45% Loosely correlated | -4.09% | ||
| VYGR - KYTX | 44% Loosely correlated | -3.19% | ||
More | ||||
Moving higher for three straight days is viewed as a bullish sign. Keep an eye on this stock for future growth. Considering data from situations where KYTX advanced for three days, in of 122 cases, the price rose further within the following month. The odds of a continued upward trend are .
The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 1 day, which means it's wise to expect a price bounce in the near future.
The Aroon Indicator entered an Uptrend today. In of 63 cases where KYTX Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .
The 10-day RSI Indicator for KYTX moved out of overbought territory on July 09, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 8 similar instances where the indicator moved out of overbought territory. In of the 8 cases, the stock moved lower in the following days. This puts the odds of a move lower at .
The Momentum Indicator moved below the 0 level on July 31, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on KYTX as a result. In of 46 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .
The Moving Average Convergence Divergence Histogram (MACD) for KYTX turned negative on July 13, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 22 similar instances when the indicator turned negative. In of the 22 cases the stock turned lower in the days that followed. This puts the odds of success at .
KYTX moved below its 50-day moving average on July 10, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for KYTX crossed bearishly below the 50-day moving average on July 17, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In of 5 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are .
Following a 3-day decline, the stock is projected to fall further. Considering past instances where KYTX declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
KYTX broke above its upper Bollinger Band on July 07, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. KYTX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.269) is normal, around the industry mean (19.620). P/E Ratio (0.000) is within average values for comparable stocks, (38.277). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (3.532). Dividend Yield (0.000) settles around the average of (0.020) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (420.906).
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. KYTX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.